Abstract 898P
Background
TCL are a heterogenous group of tumors with different clinical course, treatment and prognosis. Their treatment often poses a challenge for oncologist. We aimed to review current data on TCL treatments and outcomes using real-world data.
Methods
Retrospective analysis of Belarusian cancer registry (Minsk city, adults) data was performed using search criteria “ICD code: C84” and “date of diagnosis: 2010-2019”.
Results
Data on 142 patients were found. Median age at diagnosis was 63,5 years (range 22 – 86). Men comprised 55,6%. Histological structure was as follows: mycosis fungoides (MF) 55 (38.7%), peripheral TCL, not otherwise specified (NOS) 59.6%, angioimmunoblastic TCL 5 (3,5%), nasal type NK/T-cell lymphoma 3 (2,1%), anaplastic large cell lymphoma 8 (5,6%), including 2 ALK+, lymphoepitheliod lymphoma 2 (1.4%), enteropathy-associated TCL 1 (0.7%), CD30+ lymphoproliferative disease 1 (0.7%). Stages differed significantly for MF and other types of TCL. I stage was diagnosed in 54.2% and 13,6% of all MF and other TCL cases, correspondingly, II – in 22.9% and 17,3%, III – 12.5% and 30,9%, IV – 10.4% and 38,3%. Visceral organs involvement was seen in 27 (19,0%) of cases. Survival also differed with median overall survival 71 month for MF and 19 months for other types (plog-rank<0.01). Progression was seen in 34.5% of cases with median progression-free survival 63 and 20 months for MF and other TCL (plog-rank<0.01). In most cases chemotherapy was the main treatment option, with CHOP used in 64 (45.1%) cases, bendamustine in 10 (7.0%), fludarabine and FC in 8 (5.6%), methotrexate in 24 (16.9%), CVP in 12 (8.5%), gemcitabine in 13 (9.2%), GemOx in 10 (7.0%). Immunotherapeutic agents (IL-2 or interferon) were used in 17 (12.0%) cases, brentuximab vedotin in 4 (2.8%), radiotherapy in 15 (10.6%), stem cell transplantation in 3 (2.1%). In 43.1% of patients with early stage MF no systemic therapies were used.
Conclusions
TCL are rare malignancies, mostly affecting men in their 5 – 6 decade. For non-MF TCL prognosis is mostly poor. For MF OS is relatively high, though disease progression may occur even in early stage disease. Development of new treatment strategies is needed to achieve better treatment outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
M. Puchinskaya.
Funding
Has not received any funding.
Disclosure
Y. Baranau: Honoraria (self), Travel/Accommodation/Expenses: Roche; Honoraria (self), Travel/Accommodation/Expenses: Pfizer; Travel/Accommodation/Expenses: Novartis; Honoraria (self): Astellas; Honoraria (self), Travel/Accommodation/Expenses: Takeda. All other authors have declared no conflicts of interest.